ELI-002

1. 23:25
   ESMO 2026 现场信号

   The phase II AMPLIFY-7P trial evaluated camupepimut (ELI-002 7P) in resected KRAS-mutated pancreatic cancer. Watch @EileenMOReilly discuss the trial 👉 https://bit.ly/4ihh55E #ESMO2
2. 22:34
   ESMO 2026 现场信号

   The phase II AMPLIFY-7P trial evaluated camupepimut (ELI-002 7P) in resected KRAS-mutated pancreatic cancer. Watch @EileenMOReilly discuss the trial 👉 https://bit.ly/4soSBfp #ESMO2
3. 00:18
   ESMO 2026 现场信号

   $ELTX: One of our #ESMO2026 watchlist catalysts just reported.

1. 23:22
   ESMO 2026 现场信号

   Proffered paper on #PDAC by @EileenMOReilly at @myESMO #ESMO26 - AMPLIFY-7P
2. 22:45
   顶刊论文（社媒热度）

   camupepimut（ELI-002 7P）治疗mKRAS突变胰腺癌的AMPLIFY-7P二期试验未达DFS主要终点

   camupepimut治疗mKRAS突变PDAC的AMPLIFY-7P二期随机试验未达DFS主要终点，HR 0.85，P = 0.5329。患者按2:1分配至camupepimut组（n = 96）或标准治疗/观察组（n = 48），中位DFS为23.8个月对21.2个月。

3. 21:55
   ESMO 2026 现场信号

   🧬 AMPLIFY-7P: Primary DFS endpoint not met.
4. 21:03
   ESMO 2026 现场信号

   Today we’re presenting late-breaking results from our Phase 2 AMPLIFY-7P study evaluating camupepimut (ELI-002 7P) in patients with resected pancreatic cancer at #ESMO26, as well a

当前热度 25·可比范围峰值 47（10月24日 01:00）·近 24 小时可比范围变化 -30%·当前参与者 6

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。